EcoR1 Capital KLRS Position
Exited3-Fund ConvergenceEcoR1 Capital exited their position in Kalaris Therapeutics, Inc. (KLRS) in Q2 2025, after holding the stock for 2 quarters.
The position was first reported in Q1 2025 and has been tracked across 2 quarterly 13F filings.
KLRS is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 10.3% of float with 14.8 days to cover, indicating significant bearish positioning against the stock.
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Full company profile →Short Interest
10.3%
14.8 days to cover
EcoR1 Capital KLRS Position History
Frequently Asked Questions
Does EcoR1 Capital own KLRS?
No. EcoR1 Capital exited their position in Kalaris Therapeutics, Inc. (KLRS) in Q2 2025. They previously held the stock for 2 quarters.
How many hedge funds own KLRS?
3 specialist biotech hedge funds currently hold KLRS, including RTW Investments, Tang Capital Management, Redmile Group. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did EcoR1 Capital first buy KLRS?
EcoR1 Capital's position in KLRS was first reported in Q1 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is EcoR1 Capital's KLRS position increasing or decreasing?
EcoR1 Capital completely exited their KLRS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
KLRSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
EcoR1 CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →